Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

References

• Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96:3343 - 56; PMID: 11071626
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al, IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408 - 17; http://dx.doi.org/10.1056/NEJMoa062867; PMID: 17151364
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Pfeifer H. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol 2009; 21:Suppl 1 S43 - 6; http://dx.doi.org/10.1097/01.cco.0000357476.43164.6b; PMID: 19561414
   PubMedGoogle Scholar
• Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22:1200 - 6; http://dx.doi.org/10.1038/leu.2008.84; PMID: 18401416
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O’Brien SG, Litzow M, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540 - 6; http://dx.doi.org/10.1182/blood-2007-03-080689; PMID: 17715389
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542 - 51; http://dx.doi.org/10.1056/NEJMoa055104; PMID: 16775235
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110:2309 - 15; http://dx.doi.org/10.1182/blood-2007-02-073528; PMID: 17496201
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O’Brien S, Nicaise C, Bleickardt E, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531 - 41; http://dx.doi.org/10.1056/NEJMoa055229; PMID: 16775234
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, et al, ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251 - 9; http://dx.doi.org/10.1056/NEJMoa0912614; PMID: 20525993
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260 - 70; http://dx.doi.org/10.1056/NEJMoa1002315; PMID: 20525995
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47:6658 - 61; http://dx.doi.org/10.1021/jm049486a; PMID: 15615512
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94:1765 - 9; http://dx.doi.org/10.1038/sj.bjc.6603170; PMID: 16721371
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, et al, Nordic CML Study Group (NCMLSG). Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia 2013; 27:1520 - 6; http://dx.doi.org/10.1038/leu.2013.19; PMID: 23328954
   PubMed Web of Science ®Google Scholar
• Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49:615 - 9; http://dx.doi.org/10.1080/10428190801896103; PMID: 18398720
   PubMed Web of Science ®Google Scholar
• Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110:4055 - 63; http://dx.doi.org/10.1182/blood-2007-07-102061; PMID: 17720881
   PubMed Web of Science ®Google Scholar
• Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007; 104:13283 - 8; http://dx.doi.org/10.1073/pnas.0702654104; PMID: 17684099
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25:1035 - 44; http://dx.doi.org/10.1038/nbt1328; PMID: 17721511
   PubMed Web of Science ®Google Scholar
• Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85:387 - 98; http://dx.doi.org/10.1111/j.1600-0609.2010.01501.x; PMID: 20662899
   PubMed Web of Science ®Google Scholar
• Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127:330 - 9; http://dx.doi.org/10.1016/j.clim.2008.02.006; PMID: 18395492
   PubMed Web of Science ®Google Scholar
• Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105:2473 - 9; http://dx.doi.org/10.1182/blood-2004-07-2527; PMID: 15572591
   PubMed Web of Science ®Google Scholar
• Chen J, Schmitt A, Chen B, Rojewski M, Rübeler V, Fei F, Yu Y, Yu X, Ringhoffer M, von Harsdorf S, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med 2008; 12:5B 2107 - 18; http://dx.doi.org/10.1111/j.1582-4934.2008.00234.x; PMID: 18194453
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094 - 100; http://dx.doi.org/10.1038/nm.2438; PMID: 21873989
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Anticancer effects of imatinib via immunostimulation. Nat Med 2011; 17:1050 - 1; http://dx.doi.org/10.1038/nm.2429; PMID: 21900920
   PubMed Web of Science ®Google Scholar
• Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114:379 - 88; http://dx.doi.org/10.1172/JCI21102; PMID: 15286804
   PubMed Web of Science ®Google Scholar
• Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, et al. Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome. Oncoimmunology 2013; 2:e23080; http://dx.doi.org/10.4161/onci.23080; PMID: 23525357
   PubMedGoogle Scholar
• Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 2012; 120:4533 - 43; http://dx.doi.org/10.1182/blood-2012-02-407163; PMID: 22936666
   PubMed Web of Science ®Google Scholar
• Poggi A, Zocchi MR. Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment. Oncoimmunology 2012; 1:214 - 6; http://dx.doi.org/10.4161/onci.1.2.18112; PMID: 22720246
   PubMed Web of Science ®Google Scholar
• Yang Y, Lizée G, Hwu P. Strong emerging rationale for combining oncogene-targeted agents with immunotherapy. Oncoimmunology 2013; 2:e22730; http://dx.doi.org/10.4161/onci.22730; PMID: 23524978
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Porkka K, Mustjoki S. Immunomodulatory Effects of Tyrosine Kinase Inhibitors. International Trends in Immunity 2013; 01:22 - 33
   Google Scholar
• Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, Szpurka H, Maciejewski JP. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111:1366 - 77; http://dx.doi.org/10.1182/blood-2007-04-084814; PMID: 17962511
   PubMed Web of Science ®Google Scholar
• Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14:2484 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-07-4393; PMID: 18413841
   PubMed Web of Science ®Google Scholar
• Seggewiss R, Price DA, Purbhoo MA. Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy 2008; 10:633 - 41; http://dx.doi.org/10.1080/14653240802317639; PMID: 18836918
   PubMed Web of Science ®Google Scholar
• Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104:1094 - 9; http://dx.doi.org/10.1182/blood-2003-12-4266; PMID: 15100154
   PubMed Web of Science ®Google Scholar
• Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Döhner H, Bunjes D, et al. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunol Immunother 2007; 56:849 - 61; http://dx.doi.org/10.1007/s00262-006-0232-9; PMID: 17009043
   PubMed Web of Science ®Google Scholar
• Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111:4415 - 6; http://dx.doi.org/10.1182/blood-2008-02-138701; PMID: 18398058
   PubMed Web of Science ®Google Scholar
• Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, Götz M, Guillaume P, Döhner H, Bunjes D, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008; 36:1297 - 308; http://dx.doi.org/10.1016/j.exphem.2008.05.002; PMID: 18619726
   PubMed Web of Science ®Google Scholar
• Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010; 91:799 - 807; http://dx.doi.org/10.1007/s12185-010-0565-1; PMID: 20405252
   PubMed Web of Science ®Google Scholar
• Hassold N, Seystahl K, Kempf K, Urlaub D, Zekl M, Einsele H, Watzl C, Wischhusen J, Seggewiss-Bernhardt R. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer 2012; 131:E916 - 27; http://dx.doi.org/10.1002/ijc.27537; PMID: 22419518
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 2013; 27:914 - 24; http://dx.doi.org/10.1038/leu.2012.348; PMID: 23192016
   PubMed Web of Science ®Google Scholar
• Valent JN, Schiffer CA. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res 2011; 35:e1 - 3; http://dx.doi.org/10.1016/j.leukres.2010.08.022; PMID: 20888043
   PubMedGoogle Scholar
• Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009; 94:135 - 9; http://dx.doi.org/10.3324/haematol.13151; PMID: 19066329
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; 116:772 - 82; http://dx.doi.org/10.1182/blood-2009-12-256800; PMID: 20413659
   PubMed Web of Science ®Google Scholar
• Lee SJ, Jung CW, Kim DY, Lee KH, Sohn SK, Kwak JY, Kim HJ, Kim IH, Park S, Kim DH. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. Am J Hematol 2011; 86:346 - 50; http://dx.doi.org/10.1002/ajh.21980; PMID: 21442637
   PubMed Web of Science ®Google Scholar
• Ilander M, Hekim C, Mustjoki S. Immunology and immunotherapy of chronic myeloid leukemia. Curr Hematol Malig Rep 2014; 9:17 - 23; http://dx.doi.org/10.1007/s11899-013-0190-1; PMID: 24390549
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6:1018 - 23; http://dx.doi.org/10.1038/79526; PMID: 10973322
   PubMed Web of Science ®Google Scholar
• Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, Gostick E, Yamada K, Melenhorst J, Childs R, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102:2892 - 900; http://dx.doi.org/10.1182/blood-2003-01-0150; PMID: 12829610
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H, Porkka K, Price DA, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011; 25:1587 - 97; http://dx.doi.org/10.1038/leu.2011.135; PMID: 21647156
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, Voglová J, Sinisalo M, Flochová E, Vakkila J, et al. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 2011; 6:e23022; http://dx.doi.org/10.1371/journal.pone.0023022; PMID: 21857985
   PubMed Web of Science ®Google Scholar
• Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008; 73:975 - 83; http://dx.doi.org/10.1002/cyto.a.20643; PMID: 18785267
   PubMed Web of Science ®Google Scholar
• Kummer JA, Kamp AM, Tadema TM, Vos W, Meijer CJ, Hack CE. Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol 1995; 100:164 - 72; http://dx.doi.org/10.1111/j.1365-2249.1995.tb03619.x; PMID: 7697916
   PubMed Web of Science ®Google Scholar
• Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637 - 50; http://dx.doi.org/10.1084/jem.20091918; PMID: 20156971
   PubMed Web of Science ®Google Scholar
• Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22:371 - 83; http://dx.doi.org/10.1016/j.immuni.2005.02.003; PMID: 15780993
   PubMed Web of Science ®Google Scholar
• Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel PM. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 1990; 75:2005 - 16; PMID: 1692492
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23:1398 - 405; http://dx.doi.org/10.1038/leu.2009.46; PMID: 19295545
   PubMed Web of Science ®Google Scholar
• Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011; 52:668 - 79; http://dx.doi.org/10.3109/10428194.2010.550074; PMID: 21271862
   PubMed Web of Science ®Google Scholar
• Ashley CW, Baecher-Allan C. Cutting Edge: Responder T cells regulate human DR+ effector regulatory T cell activity via granzyme B. J Immunol 2009; 183:4843 - 7; http://dx.doi.org/10.4049/jimmunol.0900845; PMID: 19801510
   PubMed Web of Science ®Google Scholar
• Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Har-Noy M, Larmonier N, Katsanis E. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood 2011; 117:1555 - 64; http://dx.doi.org/10.1182/blood-2010-06-288621; PMID: 21123824
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35:692 - 706; http://dx.doi.org/10.1016/j.ctrv.2009.08.004; PMID: 19733976
   PubMed Web of Science ®Google Scholar